Literature DB >> 23494669

Expression of survivin and its four splice variants in colorectal cancer and its clinical significances.

Quan-Xing Ge1, Yu-Yuan Li, Yu-Qiang Nie, Wen-Ge Zuo, Yan-Lei Du.   

Abstract

The aim of this study was to investigate the clinical significances of the mRNA expression of survivin gene and its four splice variants in the pathogenesis of colorectal cancer (CRC). CRC samples, matched adjacent tissues, and normal tissues were collected from surgical resections of 39 patients with histologically confirmed diagnosis. The mRNA expression of survivin and its four splice variants, that is, survivin-△Ex3, survivin-2B, survivin-3B, and survivin-2α, was detected using semiquantitative PCR and RT-PCR. Carcinoembryonic antigen (CEA) CAM5 was determined as control. The mRNA expression rates of survivin, survivin-△Ex3, survivin-2B, survivin-3B, surviving-2α, and CEA CAM5 in CRC samples were significantly higher than those in adjacent tissues (P < 0.01) and those in normal tissues (P < 0.01). The mRNA levels of the above variants in CRC samples were also significantly higher than those in adjacent tissues (P < 0.01) and those in normal tissues (P < 0.01). The mRNA levels of survivin, survivin-2B, and survivin-2α were not associated with any clinical variable of patients, while the levels of survivin-△Ex3 and survivin-3B were associated with lymphoid metastasis and Dukes grade (P < 0.05), and survivin-△Ex3 was associated with invasiveness. We concluded that mRNA expression rates and levels of survivin and its four splice variants elevated in CRC tissues, and expression levels of survivin-△Ex3 and survivin-3B were positively associated with tumor aggression.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23494669     DOI: 10.1007/s12032-013-0535-6

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  44 in total

1.  Significant elevation of survivin and livin expression in human colorectal cancer: inverse correlation between expression and overall survival.

Authors:  Ren Chong Xi; Wang Shou Biao; Zhang Zhi Gang
Journal:  Onkologie       Date:  2011-08-19

2.  High survivin expression as a predictor of poor response to preoperative chemoradiotherapy in locally advanced rectal cancer.

Authors:  Kyubo Kim; Eui Kyu Chie; Hong-Gyun Wu; Sang Gyun Kim; Seung-Hee Lee; Gyeong Hoon Kang; Chang Lim Hyun; Sung W Ha
Journal:  Int J Colorectal Dis       Date:  2011-03-19       Impact factor: 2.571

3.  Do the survivin (BIRC5) splice variants modulate or add to the prognostic value of total survivin in breast cancer?

Authors:  Paul N Span; Vivianne C G Tjan-Heijnen; Joop J T M Heuvel; Jacques B de Kok; John A Foekens; Fred C G J Sweep
Journal:  Clin Chem       Date:  2006-07-27       Impact factor: 8.327

4.  Correlation between transcriptional expression of survivin isoforms and clinicopathological findings in human colorectal carcinomas.

Authors:  Keiji Suga; Tetsuhisa Yamamoto; Yoshitaka Yamada; Shin-Ichi Miyatake; Toshimasa Nakagawa; Nobuhiko Tanigawa
Journal:  Oncol Rep       Date:  2005-05       Impact factor: 3.906

5.  Molecular staging for survival prediction of colorectal cancer patients.

Authors:  Steven Eschrich; Ivana Yang; Greg Bloom; Ka Yin Kwong; David Boulware; Alan Cantor; Domenico Coppola; Mogens Kruhøffer; Lauri Aaltonen; Torben F Orntoft; John Quackenbush; Timothy J Yeatman
Journal:  J Clin Oncol       Date:  2005-05-20       Impact factor: 44.544

6.  Survivin-3B gene decreases the invasion-inhibitory effect of colon cancer cells with 5-fluorouracil.

Authors:  Katsuji Sawai; Takanori Goi; Yasuo Hirono; Kanji Katayama; Akio Yamaguchi
Journal:  Oncol Res       Date:  2010       Impact factor: 5.574

7.  Expression of survivin protein in human colorectal carcinogenesis.

Authors:  Lian-Jie Lin; Chang-Qing Zheng; Yu Jin; Ying Ma; Wei-Guo Jiang; Tie Ma
Journal:  World J Gastroenterol       Date:  2003-05       Impact factor: 5.742

8.  Expression of survivin and its significance in colorectal cancer.

Authors:  Wei-Chang Chen; Qiang Liu; Jian-Xin Fu; Su-Ya Kang
Journal:  World J Gastroenterol       Date:  2004-10-01       Impact factor: 5.742

Review 9.  Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough?

Authors:  F Graziano; S Cascinu
Journal:  Ann Oncol       Date:  2003-07       Impact factor: 32.976

10.  High survivin expression as a risk factor in patients with anal carcinoma treated with concurrent chemoradiotherapy.

Authors:  Ingeborg Fraunholz; Claus Rödel; Luitpold Distel; Marget Rave-Fränk; Daniela Kohler; Stefan Falk; Franz Rödel
Journal:  Radiat Oncol       Date:  2012-06-14       Impact factor: 3.481

View more
  4 in total

1.  Overexpression of nicotinamide N-methyltransferase in HSC-2 OSCC cell line: effect on apoptosis and cell proliferation.

Authors:  Riccardo Seta; Marco Mascitti; Roberto Campagna; Davide Sartini; Stefania Fumarola; Andrea Santarelli; Michele Giuliani; Monia Cecati; Lorenzo Lo Muzio; Monica Emanuelli
Journal:  Clin Oral Investig       Date:  2018-06-07       Impact factor: 3.573

2.  GRHL3 Promotes Tumor Growth and Metastasis via the MEK Pathway in Colorectal Cancer.

Authors:  Lin Tan; Weiming Qu; Dajun Wu; Minji Liu; Qian Wang; Qiongjia Ai; Hongsai Hu; Min Chen; Weishun Chen; Hongbing Zhou
Journal:  Anal Cell Pathol (Amst)       Date:  2021-11-30       Impact factor: 2.916

3.  Hydroxycamptothecin induces apoptosis and inhibits tumor growth in colon cancer by the downregulation of survivin and XIAP expression.

Authors:  Bojian Fei; Alfred L Chi; Yuan Weng
Journal:  World J Surg Oncol       Date:  2013-05-30       Impact factor: 2.754

4.  Early diagnostic value of survivin and its alternative splice variants in breast cancer.

Authors:  Salma Khan; Heather Ferguson Bennit; David Turay; Mia Perez; Saied Mirshahidi; Yuan Yuan; Nathan R Wall
Journal:  BMC Cancer       Date:  2014-03-12       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.